Proteins, Cells, and Immunity in the Moyamoya Disease: An Overview
The pathogenesis of moyamoya disease (MMD) has not been fully clarified. A multifactorial mode of inheritance may be involved in disease occurrence or susceptibility.
The rare incidence and low mortality rate of the disease, the limited availability of surgical specimens from affected internal carotid arteries, and the lack of animal models of MMD represent obstacles to the basic research of MMD. Because of these limitations, the analysis of peripheral blood and cerebrospinal fluid (CSF) of patients has been an effective means of investigating the pathogenesis of this disease.
This chapter describes the role of proteins, cells, and immunity in the pathogenesis of MMD.
KeywordsHepatocyte Growth Factor Moyamoya Disease Superficial Temporal Artery Intimal Thickening Endothelial Adhesion Molecule
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Ikezaki K, Kono S, Fukui M (2001) Etiology of moyamoya disease: pathology, pathophysiology, and genetics. In: Ikezaki K, Loftus CM (eds) Moyamoya disease. Rolling Meadows: American Association of Neurological SurgeonsGoogle Scholar
Kono S, Oka K, Sueishi K (1990) Histopathologic and morphometric studies of leptomeningeal vessels in moyamoya disease. Stroke 21:1044–1050PubMedCrossRefGoogle Scholar
Hoshimaru M, Takahashi JA, Kikuchi H et al (1991) Possible roles of basic fibroblast growth factor in the pathogenesis of moyamoya disease: an immunohistochemical study. J Neurosurg 75:267–270PubMedCrossRefGoogle Scholar
Malek AM, Connors S, Robertson RL et al (1997) Elevation of cerebrospinal fluid levels of basic fibro-blast growth factor in moyamoya and central nervous system disorders. Pediatr Neurosurg 27:182–189PubMedCrossRefGoogle Scholar
Suzui H, Hoshimaru M, Takahashi JA et al (1994) Immunohistochemical reactions for fibroblast growth factor receptor in arteries of patients with moyamoya disease. Neurosurgery 35:20–25PubMedCrossRefGoogle Scholar
Takahashi A, Sawamura Y, Houkin K et al (1993) The cerebrospinal fluid in patients with moyamoya disease (spontaneous occlusion of the circle of Willis) contains high level of basic fibroblast growth factor. Neurosci Lett 160:214–216PubMedCrossRefGoogle Scholar
Yoshimoto T, Houkin K, Takahashi A et al (1996) Angiogenic factors in moyamoya disease. Stroke 27:2160–2165PubMedCrossRefGoogle Scholar
Hojo M, Hoshimaru M, Miyamoto S et al (1998) Role of transforming growth factor-beta1 in the pathogenesis of moyamoya disease. J Neurosurg 89:623–629PubMedCrossRefGoogle Scholar
Aoyagi M, Fukai N, Sakamoto H et al (1991) Altered cellular responses to serum mitogens, including platelet-derived growth factor, in cultured smooth muscle cells derived from arteries of patients with moyamoya disease. J Cell Physiol 147:191–198PubMedCrossRefGoogle Scholar
Kubo H (1993) Angiogenesis on encephalo-myo-synangiosis. The effect of basic fibroblast growth factor. Nippon Geka Hokan 62:82–91 (in Japanese)PubMedGoogle Scholar
Yamamoto M, Aoyagi M, Tajima S et al (1997) Increase in elastin gene expression and protein synthesis in arterial smooth muscle cells derived from patients with Moyamoya disease. Stroke 28: 1733–1738PubMedCrossRefGoogle Scholar
Nanba R, Kuroda S, Ishikawa T et al (2004) Increased expression of hepatocyte growth factor in cerebrospinal fluid and intracranial artery in moyamoya disease. Stroke 35:2837–2842PubMedCrossRefGoogle Scholar
Kim SK, Yoo JI, Cho BK et al (2003) Elevation of CRABP-I in the cerebrospinal fluid of patients with Moyamoya disease. Stroke 34:2835–2841PubMedCrossRefGoogle Scholar
Takagi Y, Kikuta K, Nozaki K et al (2007) Expression of hypoxia-inducing factor-1 alpha and endoglin in intimal hyperplasia of the middle cerebral artery of patients with Moyamoya disease. Neurosurgery 60:338–345PubMedCrossRefGoogle Scholar
Yoshihara T, Taguchi A, Matsuyama T et al (2008) Increase in circulating CD34-positive cells in patients with angiographic evidence of moyamoya-like vessels. J Cereb Blood Flow Metab 28:1086–1089PubMedCrossRefGoogle Scholar
Folkman J, Shing Y (1992) Angiogenesis. J Biol Chem 267:10931–10934PubMedGoogle Scholar
Isner JM, Asahara T (1999) Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest 103:1231–1236PubMedCrossRefGoogle Scholar
Jung KH, Chu K, Lee ST et al (2008) Circulating endothelial progenitor cells as a pathogenetic marker of moyamoya disease. J Cereb Blood Flow Metab 28:1795–1803PubMedCrossRefGoogle Scholar
Rafat N, Beck GCh, Peña-Tapia PG et al (2009) Increased levels of circulating endothelial progenitor cells in patients with Moyamoya disease. Stroke 40:432–438PubMedCrossRefGoogle Scholar
Masuda J, Ogata J, Yutani C (1993) Smooth muscle cell proliferation and localization of macrophages and T cells in the occlusive intracranial major arteries in moyamoya disease. Stroke 24:1960–1967PubMedCrossRefGoogle Scholar
Soriano SG, Cowan DB, Proctor MR et al (2002) Levels of soluble adhesion molecules are elevated in the cerebrospinal fluid of children with moyamoya syndrome. Neurosurgery 50:544–549PubMedGoogle Scholar
Yamamoto M, Aoyagi M, Fukai N et al (1999) Increase in prostaglandin E(2) production by interleukin-1beta in arterial smooth muscle cells derived from patients with moyamoya disease. Circ Res 85:912–918PubMedCrossRefGoogle Scholar
Noda A, Suzuki Y, Takayasu M et al (2000) Elevation of nitric oxide metabolites in the cerebrospinal fluid of patients with moyamoya disease. Acta Neurochir (Wien) 142:1275–1280CrossRefGoogle Scholar
Kim J, Kim SK, Wang KC et al (2004) SEREX identification of the autoantibodies that are prevalent in the cerebrospinal fluid of patients with moyamoya disease. Biotechnol Lett 26:585–588PubMedCrossRefGoogle Scholar
Tsuda H, Hattori S, Tanabe S et al (1997) Thrombophilia found in patients with moyamoya disease. Clin Neurol Neurosurg 99 (Suppl 2):S229–233PubMedGoogle Scholar